Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ProteoTech logo — Advancing Therapeutics and Diagnostics for Amyloid Diseases...

ProteoTech

Advancing Therapeutics and Diagnostics for Amyloid Diseases Since 1996

Founded 1996 2-10 employees Series Unknown Total: $10.54M Biotechnology, Health Care

General Information

Company Name ProteoTech
Founded Year 1996
Employees 2-10
Industries Biotechnology, Health Care
Funding Stage Series Unknown
Social

Get notified when ProteoTech moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ProteoTech

ProteoTech is a US-based pharmaceutical company founded in 1996, dedicated to advancing therapeutics and diagnostics for amyloid diseases. The company's product lineup includes Exebryl-1, which targets the prevention of beta-amyloid protein formation, PeptiClere for Alzheimer's treatment, Synuclere for Parkinson's disease, and Systebryl for systemic amyloidosis associated with type 2 diabetes. At a last investment round in June 2011, ProteoTech secured $10.02M in venture capital. Based in Kirkland, Washington, ProteoTech aims to provide solutions for amyloid diseases, including Alzheimer's and Parkinson's.

Taxonomy: Pharmaceuticals, Therapeutics, Diagnostics, Amyloid Diseases, Alzheimer's Disease, Parkinson's Disease, Drug Development, Molecule Compound, Medical Research, Nasal Spray, Systemic Amyloidosis, Type 2 Diabetes, Proteins, Neurodegenerative Diseases

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 28 Jun 2011
Debt Financing •••••• - 28 Apr 2009

ProteoTech Alternatives & Competitors

ProteoTech vs
Senexis Limited
Senexis Limited United Kingdom

Small-molecule therapies targeting amyloid protein toxicity

Unknown
3 employees
Biotechnology, Life Sciences
ProteoTech vs
Cognoptix
Cognoptix United States

The Eye Scan for Alzheimer's Early Insight

Series Unknown
3 employees
Biotechnology, Health Care
ProteoTech vs
Anavex Life Sciences
Anavex Life Sciences United States

Anavex utilizes genomic biomarkers in precision medicine to treat severe neurological disorders

47 employees

FAQ About ProteoTech

Advancing Therapeutics and Diagnostics for Amyloid Diseases Since 1996
ProteoTech was founded in 1996.
ProteoTech operates in the following industries: Biotechnology, Health Care.
ProteoTech has approximately 2-10 employees.
ProteoTech has completed 2 funding rounds, raising a total of $10.54M. The latest funding stage is Series Unknown.
Top alternatives and competitors to ProteoTech include Senexis Limited, Cognoptix, Anavex Life Sciences, PharmaKure Limited, ALSP, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ProteoTech and Senexis Limited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ProteoTech and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy